Deferoxamine Protective Effect in Preventing Nephrotoxicity in Children Under Treatment with Doxorubicin: A Randomized Clinical Trial

Authors

  • Fazl Saleh Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
  • Mahdi Shahriari Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
  • Mehran Karimi Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
  • Mitra Basiratnia Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
  • Nader Shakibazad Assistant Professor of Pediatric Hematology and Oncology, Bushehr University of Medical Sciences, Bushehr, Iran
  • Omid Reza Zekavat Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
  • Soheila Zareifar Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Abstract:

Background: Nephrotoxicity secondary to doxorubicin (DOX) may be associated with high morbidity and mortality rates. We aimed to assess the efficacy of Deferoxamine (DFO) in preventing DOX-induced nephrotoxicity in pediatric malignancy. Methods: This Parallel-group randomized clinical trial was done on 62 children aged 2-18 years who had new onset malignancy treated with DOX. They were randomly assigned in three groups; group 1 (no intervention, n=21), group II (DFO 10 times DOX dose, n=20), group III (DFO 50mg/kg, n=21). Patients in the intervention groups received DFO concomitant with DOX 8-hour intravenous infusion in each chemotherapy course. Blood urea nitrogen, serum creatinine, electrolytes, calcium, phosphorus, magnesium and albumin levels, urine microalbumin, urine protein/creatinine ratio, and urine N-acetyl-β-D- glucosaminidase (NAG) as well as findings of kidney ultrasonography were compared between the groups after the last course of chemotherapy. The primary outcome was to compare the radiologic and serologic markers of glomerular and tubular damage between the 3 groups. Results: Sixty patients were analyzed. Patients treated with DFO 10 times the dose of DOX had significantly lower urine NAG level compared to the control group (P=0.032). No significant renal damage was reported in their ultrasonography in the 3 groups. DFO was safely tolerated without any adverse effect. Conclusion: DFO with 10-times the DOX dose may effectively prevent DOX-induced nephrotoxicity at least at the molecular level. Increasing the dose of DFO is not accompanied by better efficacy. Trial registration: IRCT2016021915666N3

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

The protective role of deferoxamine in the prevention of doxorubicin-induced hepatic fibrosis in children: A randomized controlled clinical trial

Background: This study aimed to investigate the protective effects of Deferoxamine (DFO) against hepatic fibrosis in treatment of pediatric cancer patients. Methods: In this prospective randomized controlled trial, 61 treatment-naïve children (2-18 years) with different types of cancer who referred to a tertiary teaching hospital in South of Iran were enrolled. They were randomly assigned to 3...

full text

Effect of Combined versus Monotherapy with Deferoxamine and Deferiprone in Iron Overloaded Thalassemia Patients: a Randomized Clinical Trial

Background: Patients with transfusional iron overload have depended on iron chelation therapy and improving chelation regimens have been of the highest priority. The aim of this study was to compare effect of combined versus monotherapy with Deferoxamine (DFO) and Deferiprone (DFP) in iron overloaded beta thalassemia (BT) major patients Materials and Methods We studied 36 BT major patients (mea...

full text

Doxorubicin Induced Nephrotoxicity: Protective Effect of Nicotinamide

Introduction. Nephrotoxicity is one of the important side effects of anthracycline antibiotics. The aim of this study was to investigate the effects of nicotinamide (NAD), an antioxidant agent, against nephrotoxicity induced by doxorubicin (DXR). Methods. The rats were divided into control, NAD alone, doxorubicin (20 mg/kg, i.p.) and DXR plus NAD (200 mg/kg, i.p.) groups. At the end of the 10th...

full text

Evaluation of Hepatoprotective Effect of Silymarin Among Under Treatment Tuberculosis Patients: A Randomized Clinical Trial

Hepatic toxicity is the most serious adverse effect of anti tuberculosis drugs. This study was performed to evaluate efficacy of silymarin as a hepatoprotective herbal agent. In a randomized double blind clinical trial 70 new cases of pulmonary tuberculosis were divided into two groups. The intervention group was assigned to receive silymarin and the control group received placebo. Tuberculosis...

full text

Evaluation of Hepatoprotective Effect of Silymarin Among Under Treatment Tuberculosis Patients: A Randomized Clinical Trial

Hepatic toxicity is the most serious adverse effect of anti tuberculosis drugs. This study was performed to evaluate efficacy of silymarin as a hepatoprotective herbal agent. In a randomized double blind clinical trial 70 new cases of pulmonary tuberculosis were divided into two groups. The intervention group was assigned to receive silymarin and the control group received placebo. Tuberculosis...

full text

Effect of Caffeine on Coughing in Children Aged 3-36 Months: A Randomized Clinical Trial

Aims: Coughing is one of the most common clinical complaints in pediatric medicine. Since caffeine, as a central nervous system stimulant from methylxanthine, inhibits tumor necrosis factor-alpha (TNFα) and leukotriene synthesis and reduces inflammation and initiates the immune process, the aim of this study was to determine the effect of caffeine on coughing in children aged 3-36 months. Mater...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 11  issue 2

pages  51- 56

publication date 2019-06

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023